DE69928778D1 - Anwendung von Komplexen von kationischen Liposomen und Polydeoxyribonukleotiden wie Arzneimitteln - Google Patents

Anwendung von Komplexen von kationischen Liposomen und Polydeoxyribonukleotiden wie Arzneimitteln

Info

Publication number
DE69928778D1
DE69928778D1 DE69928778T DE69928778T DE69928778D1 DE 69928778 D1 DE69928778 D1 DE 69928778D1 DE 69928778 T DE69928778 T DE 69928778T DE 69928778 T DE69928778 T DE 69928778T DE 69928778 D1 DE69928778 D1 DE 69928778D1
Authority
DE
Germany
Prior art keywords
complexes
polydeoxyribonucleotides
cationic liposomes
drugs
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69928778T
Other languages
English (en)
Other versions
DE69928778T2 (de
Inventor
Roberto Porta
Laura Ferro
Fabio Trento
Claudio Nastruzzi
Elisabetta Esposito
Enea Menegatti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gentium SRL
Original Assignee
Gentium SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gentium SRL filed Critical Gentium SRL
Priority claimed from AU35010/99A external-priority patent/AU776014B2/en
Publication of DE69928778D1 publication Critical patent/DE69928778D1/de
Application granted granted Critical
Publication of DE69928778T2 publication Critical patent/DE69928778T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DE69928778T 1999-06-08 1999-06-08 Anwendung von Komplexen von kationischen Liposomen und Polydeoxyribonukleotiden wie Arzneimitteln Expired - Lifetime DE69928778T2 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP99111118A EP1059092B1 (de) 1999-06-08 1999-06-08 Anwendung von Komplexen von kationischen Liposomen und Polydeoxyribonukleotiden wie Arzneimitteln
US09/330,215 US6767554B2 (en) 1999-06-08 1999-06-11 Use of complexes among cationic liposomes and polydeoxyribonucleotides and medicaments
CA002274419A CA2274419A1 (en) 1999-06-08 1999-06-11 Use of complexes among cationic liposomes and polydeoxyribonucleotides as medicaments
AU35010/99A AU776014B2 (en) 1999-06-11 1999-06-11 Use of complexes among cationic liposomes and polydeoxyribonucleotides as medicaments
KR1019990021947A KR100676492B1 (ko) 1999-06-08 1999-06-12 양이온성 리포솜 및 폴리데옥시리보누클레오티드 사이의 복합체의 약제로서의 용도
JP16700999A JP4598908B2 (ja) 1999-06-08 1999-06-14 カチオン性リポソームとポリデオキシリボヌクレオチドとの複合体

Publications (2)

Publication Number Publication Date
DE69928778D1 true DE69928778D1 (de) 2006-01-12
DE69928778T2 DE69928778T2 (de) 2006-07-06

Family

ID=32330163

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69928778T Expired - Lifetime DE69928778T2 (de) 1999-06-08 1999-06-08 Anwendung von Komplexen von kationischen Liposomen und Polydeoxyribonukleotiden wie Arzneimitteln

Country Status (9)

Country Link
US (1) US6767554B2 (de)
EP (1) EP1059092B1 (de)
JP (1) JP4598908B2 (de)
KR (1) KR100676492B1 (de)
AT (1) ATE311907T1 (de)
CA (1) CA2274419A1 (de)
DE (1) DE69928778T2 (de)
DK (1) DK1059092T3 (de)
ES (1) ES2251134T3 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4115833B2 (ja) 2000-10-12 2008-07-09 ユニバーシティー、オブ、メディシン、アンド、デンティストリー、オブ、ニュージャージー オリゴヌクレオチドが促進する合体
EP2108362B1 (de) 2002-06-26 2013-05-29 MediGene AG Ein kationisches Trägersystem beinhaltend Taxane
JP2006193461A (ja) * 2005-01-13 2006-07-27 Pola Chem Ind Inc 毛髪用の洗浄料
ITMI20051303A1 (it) * 2005-07-08 2007-01-09 Inxel S R L Metodo per la produzione di vernici in polvere termoindurenti particolarmente per l'applicazione mediante impianti elettrostatici
EP1872787A1 (de) * 2006-06-27 2008-01-02 Gentium S.p.A. Verwendung von Defibrotide als Heparanasehemmer
JPWO2008093848A1 (ja) * 2007-02-02 2010-05-20 サンスター株式会社 ホスファチジルコリンを含有する炎症マーカー低減組成物
EP2103689A1 (de) * 2008-03-19 2009-09-23 Gentium S.p.A. Synthetische Phosphodiester-Oligonukleotide und deren therapeutische Verwendungen
US20100279353A1 (en) * 2009-04-30 2010-11-04 Shiu Nan Chen Process of producing fibrinolytic enzyme from mushroom
JP5142295B2 (ja) * 2009-05-08 2013-02-13 独立行政法人農業・食品産業技術総合研究機構 ベシクル及びその製法
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
AU2010363814B2 (en) 2010-11-12 2016-05-19 Gentium S.R.L. Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD).
GB201204632D0 (en) * 2012-03-16 2012-05-02 Univ Belfast Delivery system
KR20150044877A (ko) 2012-06-22 2015-04-27 젠티엄 에스피에이 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
US11086970B2 (en) 2013-03-13 2021-08-10 Blue Belt Technologies, Inc. Systems and methods for using generic anatomy models in surgical planning
KR101534276B1 (ko) * 2014-07-18 2015-07-07 주식회사 에스씨301테라피 지방 이식 수술 후 지방세포 성장 및 생착 증진을 위한 조성물
EP3026122A1 (de) 2014-11-27 2016-06-01 Gentium S.p.A. Zellenbasiertes Verfahren zur Bestimmung der Wirksamkeit von Defibrotid
CN111132663A (zh) 2017-08-03 2020-05-08 爵士制药爱尔兰有限公司 包含高浓度核酸的制剂
EP3778572A4 (de) 2018-03-27 2021-12-22 NOF Corporation Neues kationisches lipid mit verbesserter intrazellulärer dynamik
MX2020010689A (es) 2018-04-12 2021-01-20 Jazz Pharmaceuticals Inc Defibrotida para la prevencion y tratamiento del sindrome de liberacion de citocinas y la neurotoxicidad asociada con la inmunodeplecion.
KR102144615B1 (ko) * 2018-08-09 2020-08-13 장건주 폴리데옥시리보뉴클레오타이드를 포함하는 마이셀, 약물 전달체 및 이의 제조방법
KR102132478B1 (ko) * 2018-11-15 2020-07-10 (주)진우바이오 히알루론산-폴리데옥시리보뉴클레오타이드 복합체와 이를 활용한 필름 및 이의 제조방법
US20220023533A1 (en) 2018-12-07 2022-01-27 Jazz Phrmaceticals Ireland Limited Subcutaneous delivery of high concentration formulations
US20220354793A1 (en) 2019-09-26 2022-11-10 Nof Corporation Lipid nanoparticle lyophilized composition
EP4110287A1 (de) 2020-02-28 2023-01-04 Jazz Pharmaceuticals Ireland Limited Abgabe von niedrigviskosen formulierungen
WO2022234101A1 (en) 2021-05-06 2022-11-10 Jazz Pharmaceuticals Ireland Limited Defibrotide for the treatment and prevention of acute respiratory distress syndrome
WO2024106783A1 (ko) * 2022-11-14 2024-05-23 주식회사 스템온 폴리데옥시리보뉴클레오티드를 포함하는 엑소좀, 이를 포함하는 조성물 및 이의 제조방법
CN115737470B (zh) * 2022-11-25 2024-09-10 润辉生物技术（威海）有限公司 一种肌肽-pdrn复合物及其制备方法和应用
CN115836982B (zh) * 2022-12-30 2024-02-06 南京乐韬生物科技有限公司 一种含pdrn的纳米乳液及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1043823B (it) 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
DE3017154A1 (de) 1980-05-05 1981-11-12 Hoechst Ag, 6000 Frankfurt Verfahren zur herstellung von 2-chlor-1,1,1,2,3,3,3,-heptafluor-propan
HU192909B (en) * 1985-01-17 1987-07-28 Chinoin Gyogyszer Es Vegyeszet Process for producing interfuranylene-prostacycline derivatives
IT1190313B (it) 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
DE68916439T2 (de) * 1988-10-05 1994-10-20 Vestar Inc Verfahren zur herstellung von liposomen mit verbesserter stabilität während des trocknens.
ES2055907T3 (es) * 1989-03-07 1994-09-01 Genentech Inc Conjugados covalentes de lipidos y oligonucleotidos.
EP0451791A2 (de) * 1990-04-12 1991-10-16 Hoechst Aktiengesellschaft Langwirksame Liposomenpräparate von Peptidarzneistoffen und Verfahren zu ihrer Herstellung
SG44743A1 (en) 1991-11-01 1997-12-19 Solvay Process for the preparation of 1,1,1,2,3,3,3,-heptafluoropropane (R 227)
IT1252174B (it) * 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
ES2093872T3 (es) 1992-03-26 1997-01-01 Solvay Procedimiento para la reactivacion de un catalizador de carbon activo empleado para la preparacion de 1,1,1,2,3,3,3-heptafluoropropano (r 227).
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
DE4323054A1 (de) 1993-07-14 1995-01-19 Hoechst Ag Verfahren zur Herstellung von 2-H-Heptafluorpropan
US6071890A (en) * 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5908777A (en) * 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
EP0843555B1 (de) * 1995-08-01 2003-08-27 Isis Pharmaceuticals, Inc. Liposomale oligonukleotidzusammensetzungen
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells

Also Published As

Publication number Publication date
JP4598908B2 (ja) 2010-12-15
US6767554B2 (en) 2004-07-27
DE69928778T2 (de) 2006-07-06
CA2274419A1 (en) 2000-12-11
EP1059092B1 (de) 2005-12-07
JP2001002565A (ja) 2001-01-09
US20020142029A1 (en) 2002-10-03
EP1059092A1 (de) 2000-12-13
KR20010002244A (ko) 2001-01-15
DK1059092T3 (da) 2006-03-27
KR100676492B1 (ko) 2007-01-30
ATE311907T1 (de) 2005-12-15
ES2251134T3 (es) 2006-04-16

Similar Documents

Publication Publication Date Title
DE69928778D1 (de) Anwendung von Komplexen von kationischen Liposomen und Polydeoxyribonukleotiden wie Arzneimitteln
ES2054678T5 (es) Conjugados estrella.
DE69815075D1 (de) Dimere kationische lipide auf dicystinbasis
FR2781667B1 (fr) Patch cosmetique, pharmaceutique, ou dermatologique
EP1724353A3 (de) Verfahren zur Bildung von Protein-gekoppelten lipididischen Mikropartikeln
CY1112361T1 (el) Σκευασματα για αντικαρκινικη θεραπεια που περιεχουν εκτεϊνασκιδινη 743
DZ3165A1 (fr) Composition alimentaire ou pharmaceutique utiliseepour prevenir ou traiter l'hyperoxalurie.
FR2870741B1 (fr) Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant.
ATE326536T1 (de) Herstellung von biologisch aktiven molekülen
DE60002526D1 (de) Herstellung von Tricyclodecandicarbaldehyd, Pentacyclopentadecandicarbaldehyd und der entsprechenden Dimethanole
DE69501530D1 (de) Herstellung von trans-1,4-Polybutadien mit kontrolliertem Molekulargewicht
WO1999013816A3 (en) Liposomal camptothecin formulations
DE60024093D1 (de) Magnesium/titan-alkoxidkomplexe und daraus hergestellte polymerisationskatalysatoren
DE69706146D1 (de) Taxoide, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE60041351D1 (de) Gssytem
EP0891782A3 (de) Medizinische Selbstklebefolie und Verfahren zu deren Herstellung
DE69821984D1 (de) Zubereitung enthaltend eine molekulardispersion mit erhöhter bioverfügbarkeit
BR9800349A (pt) Preparação de catalisadores à base de antimonato de vanádio utilizando sn02.xhs20
DK1011329T3 (da) 7-Methylthiooxomethyl- og 7-methylthiodioxomethyl-paclitaxeler
ID28707A (id) 1,2,4-trioksan tersubstitusi sebagai obat anti malaria dan metode pembuatannya
ITTO20010186U1 (it) ,,supporto veicolare profumi e prodotti similari,,.
ATE221895T1 (de) Chimäre oligonucleotide und ihre verwendung
IL130405A0 (en) Use of complexes among cationic liposomes and polydeoxyribonucleotides as medicaments
Wertheim All God's children got..
ES1037437U (es) Soporte modular poliposionable, aplicable como botellero.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition